Longeveron (LGVN) Stock Price

Longeveron Price

NASDAQ·CLOSED
2.48
​
Market closed

Revenue at Longeveron has contracted by 7.9% per year over the past 7 years to 1.20 M USD. Longeveron's net margin stands at -1,893.6%, down from -1,305.1% several years earlier. Analysts set a median price target of 7.14 USD, implying 187.9% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Longeveron stock price

Access this data via the Eulerpool API

Longeveron business model & stock analysis

Longeveron, Inc. is a clinical stage biotechnology company. The company is headquartered in Miami, Florida and currently employs 19 full-time employees. The company went IPO on 2021-02-12. The firm's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The firm is primarily focused on three pipeline indications, such as aging related frailty, Alzheimer's disease (AD), acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The firm has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Frequently asked questions about Longeveron

Analysts currently set an average price target of 7.00 USD for the Longeveron stock (median: 7.14 USD), implying +182.2 % versus the latest price. The consensus is based on 8 analyst ratings.

9 analysts currently rate the Longeveron stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Longeveron to generate revenue of 1.75 M USD and earnings per share of -71.01 USD.

Converted at the current exchange rate, the Longeveron share trades at 2.21 EUR (2.48 USD).

The Longeveron share (LGVN) is listed on 1 stock exchanges, including: NASDAQ (LGVN).

The expected revenue of Longeveron is 1.75 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Longeveron is -162.82 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Longeveron is currently -0.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Longeveron stock.

The price-to-sales ratio (P/S) of Longeveron is currently 3.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Longeveron stock.

The Eulerpool Quality Score for Longeveron is 2/10.

The ISIN of Longeveron is US54303L2034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Longeveron is LGVN. The ticker symbol is used to trade Longeveron shares on the stock exchange.

Fair ValueTerminal
2.26 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
63,105.26 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Feb 12, 2021
ISIN
US54303L2034
Cusip
54303L104
Market capitalization
52.90 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.03
P/Ee 2027
-0.05
P/Ee 2028
-0.30
P/Ee 2029
0.11
P/Ee 2030
0.07
P/S
P/Se
3.25
EV/EBIT
—
P/B Ratio
9.32
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-349.35 %
Last updated Oct 12, 2026, 6:25 AM

Longeveron Peer Group

Longeveron Ticker

NASDAQ · LGVN